Work

A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx302.001

Authors: T. Bekaii-Saab, A. Starodub, B. El-Rayes, B. O’Neil, S. Shahda, K. Ciombor, A. Noonan, W. Hanna, A. Sehdev, W. Shaib, S. Mikhail, A. Neki, C. Oh, Y.Z. Li, W. Li, L. Borodyansky, C.J. Li

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Indiana University Health, Parkview Health, Winship Cancer Institute, Indiana University Hospital, The Ohio State University Wexner Medical Center, University of Tennessee Medical Center, Boston Biomedical (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2733670249

FWCI: 0.323

Cites:

Cited by: 5

Related to: 10